This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Consumer Price Index Rise 0.6%
by Zacks Equity Research
Consumer Price Index Rise 0.6%
CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?
by Mark Vickery
Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.
AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study on Farxiga in hospitalized COVID-19 patients with pre-existing health conditions fails to show statistical significance for the primary endpoint
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $161.64 in the latest trading session, marking a +0.24% move from the prior day.
J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots
by Zacks Equity Research
The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
by Zacks Equity Research
ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
by Kinjel Shah
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study
by Zacks Equity Research
Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine
by Zacks Equity Research
Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.
The Zacks Analyst Blog Highlights: Pfizer, Johnson & Johnson, Delta Air Lines, Southwest Airlines and United Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Johnson & Johnson, Delta Air Lines, Southwest Airlines and United Airlines
CDC's New Guidance Makes the Skyline Sunnier for U.S. Airlines
by Maharathi Basu
CDC's latest travel manual provides a further impetus to the U.S. airline stocks like Delta (DAL), Southwest Airlines (LUV) and American Airlines (AA), which are scaling an outstanding graph on the bourses this year.
Supernus (SUPN) Receives FDA Approval for ADHD Treatment
by Zacks Equity Research
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
by Zacks Equity Research
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
Company News for Apr 5, 2021
by Zacks Equity Research
Companies In The News Are: MU, GES, WDC, JNJ.
SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study
by Zacks Equity Research
SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.
J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant
by Zacks Equity Research
The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $165.01, moving -0.62% from the previous trading session.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NIKE, Morgan Stanley, Deere & Co and ViacomCBS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, NIKE, Morgan Stanley, Deere & Co and ViacomCBS
Top Analyst Reports for Johnson & Johnson, Nike & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), NIKE, Inc. (NKE) and Morgan Stanley (MS).
J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.